Detailed Information on Publication Record
2020
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
NOVAKOVA-JIRESOVA, Alena, Katerina KOPECKOVA, Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR et. al.Basic information
Original name
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Authors
NOVAKOVA-JIRESOVA, Alena (203 Czech Republic), Katerina KOPECKOVA (203 Czech Republic), Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Lubos PETRUZELKA (203 Czech Republic), Jindrich FINEK (203 Czech Republic), Ondrej FIALA (203 Czech Republic), Peter GRELL (203 Czech Republic), Stanislav BATKO (203 Czech Republic), Zdenek LINKE (203 Czech Republic), Igor KISS (203 Czech Republic), Jana PRAUSOVA (203 Czech Republic) and Tomáš BÜCHLER (203 Czech Republic, guarantor)
Edition
CANCER MANAGEMENT AND RESEARCH, ALBANY, DOVE MEDICAL PRESS LTD, 2020, 1179-1322
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
New Zealand
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.989
RIV identification code
RIV/00216224:14110/20:00116154
Organization unit
Faculty of Medicine
UT WoS
000548281000003
Keywords in English
colorectal cancer; regorafenib; registry; survival; outcome analysis
Tags
International impact, Reviewed
Změněno: 10/8/2020 08:30, Mgr. Tereza Miškechová
Abstract
V originále
Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.